期刊文献+

宫颈癌介入化疗与全身静脉化疗的效果比较 被引量:6

A COMPARISON BETWEEN INTERVENTION CHEMOTHERAPY AND SYSTEMETIC INTRAVENOUS CHEMOTHERAPY FOR CERVICAL CANCER
下载PDF
导出
摘要 目的评价介入化疗与全身静脉化疗在宫颈癌治疗中的应用价值。方法选取Ⅱa~Ⅱb期宫颈癌病人98例,随机分为两组,介入治疗组50例先行介入栓塞化疗及放疗,全身化疗组48例先行全身静脉化疗及放疗,后继行宫颈癌根治术治疗,评定两组的近期效果及不良反应。结果两组病人化疗及放疗均明显有效,临床总有效率分别为76%及50%,两组比较差异有显著性(χ2=7.12,P<0.05);术后病理证实介入治疗组疗效亦明显优于全身化疗组(χ2=4.99,P<0.05);而术后淋巴结转移率介入治疗组明显低于全身化疗组(χ2=7.02,P<0.05);不良反应介入治疗组明显轻于静脉化疗组,差异有显著性(χ2=4.67~11.91,P<0.05、0.01)。结论宫颈癌介入栓塞化疗联合放疗治疗效果明显优于静脉化疗联合放疗,副作用明显低于静脉化疗联合放疗,是一种可行、有效的宫颈癌辅助治疗手段。 Objective To assess the value of applying intervention chemotherapy and intravenous chemotherapy for cervi cal cancer. Methods Ninety-eight patients with stage Ⅱ a -Ⅱ b cervical cancer were randomized to group A (intervention group, 50 cases) and group B (intravenous group, 48 cases). Those in group A were given embolism chemotherapy and radiothera py first; for those in group 13 were given intravenous chemotherapy and radiotherapy. All of whom were followed by radical surgery. The short term effect and adverse reactios were evaluated. Results Obvious efficacy was achieved in both chemo and radiotherapy in both groups, total effctive rate was 76% for group A and 50% for group B, the difference between them being sig nificant (x^2=7.12,P〈0.05). Pathology confirmed that the efficacy of group A was superior to that of group B (x^2=4.99,P〈 0.05). Post-operative lymph node metastatic rate was lower in group A than in group B (x^2=7.02,P〈0.05). Adverse reactions in group A were milder than group B, the difference was significant (x^2 =-4.67-11.91 ;P〈0.05,0.01). Conclusion The effect of combined intervention chemoembolization with radiotherapy for cervical cancer is better than that of systematic chemotherapy which is a feasible and effective adjunvtive therapy for cervical cancer.
出处 《齐鲁医学杂志》 2009年第5期380-382,共3页 Medical Journal of Qilu
关键词 宫颈肿瘤 药物疗法 联合 治疗结果 Cervix neoplasms Drug therapy, Combination Treatment outcome
  • 相关文献

参考文献8

  • 1KUZUYA K. Chemoradiotherapy for uterine cancer:currentstatus and perspectives[J]. IntJ ClinOncol, 2004,9(6) :458- 470.
  • 2林震琼 徐昌文 等.小细胞肺癌化疗后的病理学观察[J].中华肿瘤杂志,1988,10(6):452-454.
  • 3EIFEL P J, WINTER K, MORRIS M, et al. Pelvic irradia tion with concurrent chemotherapy versus pelvic and para aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90 01[J]. J Clin Oncol, 2004,22(5) : 872-880.
  • 4SARDI J E, BOIXADERA M A, SARDI J J. Neoadjuvant chemotherapy in cervical cancer: a new trend[J]. Curr Opin Obstet Gynecol , 2005,17(1) :43-47.
  • 5莫平,马德花,赵淑萍.介入栓塞化疗对局部晚期宫颈癌组织VEGF表达及MVD影响[J].齐鲁医学杂志,2008,23(3):213-216. 被引量:10
  • 6ADACHI S, OGASAWARA T, WAKIMOTO E, et al. Phase Ⅰ/Ⅱ study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma[J]. Cancer, 2001,91(1):74-79.
  • 7UMEKI H, YAMAGUCHI Y, TSUGATA M, et al. Neoad juvant intraarterial chemotherapy with nedaplatin, peplomycin and mitomycin C for advanced cervical cancer[J]. Gan To Kagaku Ryoho, 2003,30(3) :377-382.
  • 8STRECKER E P, HEBER R, BOOS I, et al. Preliminary experience with locoregional intraarterial chemotherapy of uterine cervical or endometrial cancer using the peripheral implantahle port system (PIPS) :a feasibility study[J]. Cardiovasc Intervent Radiol, 2003,26(2) :118-122.

二级参考文献11

  • 1ROSE P G. Locally advanced cervical cancer[J]. Curr Opin Obstet Gynecol, 2001,13 ( 1 ):65-70.
  • 2OHNO R, YOSHINAGA K, FUJITA T, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma[J]. Cancer, 2000,91:1876-1881.
  • 3SIDDIK Z H. Cisplatin: mode of cytotoxic action and molecular basis of resistance [J]. Oncogene, 2003, 22 (47):7265- 7279.
  • 4YUAN A, YU C J, CHEN W J, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer[J]. Int J Cancer, 2000,89(6) : 475- 483.
  • 5FUJIMOTO J, SAKAGUCHI H, HIROSE R, et al. Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers[J]. Br J Cancer, 1999,80 (5/6):827-833.
  • 6ADACHI S, OGASAWARA T, WAKIMOTO E, et al. Phase Ⅰ / Ⅱ study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma[J]. Cancer, 2001,91(1) :74-79.
  • 7UMEKI H, YAMAGUCHI Y, TSUGATA M, et al. Neoadjuvant intraarterial chemotherapy with nedaplatin, peplomycin and mitomycin C for advanced cervical cancer[J]. Gan To Kagaku Ryoho, 2003,30(3) :377-382.
  • 8STRECKER E P, HEBER R, BOOS I, et al. Preliminary experience with locoregional intraarterial chemotherapy of uterine cervical or endometrial cancer using the peripheral implantable port system (PIPS) : a feasibility study[J]. Cardiovasc Intervent Radiol, 2003,26(2):118-122.
  • 9NAGATA Y, ARAKI N, KIMURA H, et al. Neoadjuvant chemotherapy by transcatheter arterial infusion method for uterine cervical cancer[J]. J Vasc Interv Radiol, 2000, 11 (3) :313-319.
  • 10YOSHIE K, OSAMU I, MANABU K. Prognistic importance of histologicvascular density in cervical cancer treatedwith hypertensive intraarteri-al chemotherapy [J]. Cancer, 1993,72 (8):2394-2399.

共引文献15

同被引文献65

引证文献6

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部